Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf

NYSE - LSE

CMSC	-0.09%	21.29	$
RELX	0.66%	36.54	$
JRI	-0.4%	12.35	$
BCE	0.26%	23.46	$
CMSD	0%	21.18	$
BCC	-0.03%	78.75	$
RIO	-1.43%	103.3	$
BTI	-0.27%	56.13	$
AZN	-1.12%	162.7	$
GSK	1.08%	50.82	$
VOD	1%	16.04	$
NGG	-0.1%	79.35	$
RBGPF	0.11%	70.77	$
BP	-0.45%	42.15	$
RYCEF	-1.22%	20.5	$

Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf

BOULEVARD 06.11.2025

BOULDER, CO / ACCESS Newswire / November 6, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn^® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it will be exhibiting at MEDICA 2025 in Düsseldorf, Germany, November 17-20, 2025.

Text size:

MEDICA is one of the largest and most prestigious medical B2B trade fairs in the world, expected to attract 80,000 visitors from 72 countries and over 5,000 exhibitors, showcasing the latest innovations in medical technology, diagnostics, and healthcare consumables.

Sonoma Pharmaceuticals is aiming to expand its distributor network and showcase its products and technologies to a global audience. Interested parties are invited to visit Sonoma Pharmaceuticals' booth (D17/4) in Hall 16 to learn about its patented, innovative, safe, and effective products for scar management, atopic dermatitis, and acne, as well as wound care and eyelid infection. For more information, please contact [email protected].

"We are excited to again present our portfolio of products at MEDICA, an event renowned for bringing together thousands of distinguished attendees and exhibitors, including key decision-makers from across the globe. This event offers a unique opportunity for us to introduce potential new partners to Sonoma's products, supported by our innovative Microcyn technology," stated Amy Trombly, CEO of Sonoma Pharmaceuticals.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, the Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact [email protected].

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technological progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "opportunities," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn^® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.
[email protected]

Website: www.sonomapharma.com

SOURCE: Sonoma Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

M.King--AT